Cardiac Biomarkers Testing Market Outlook Highlights The Next Major Growth Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cardiac Biomarkers Testing Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The cardiac biomarkers testing market has experienced substantial expansion over the last several years, with projections indicating a rise from $14.95 billion in 2025 to $16.7 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.7%. This historic period of growth was largely driven by factors such as the escalating prevalence of cardiovascular diseases, enhanced public awareness regarding cardiac health, progress in laboratory diagnostic technologies, the expansion of hospital infrastructure, and an uptick in government-led healthcare programs.
The cardiac biomarkers testing industry is forecasted to expand rapidly over the coming years, reaching $25.92 billion by 2030 with a compound annual growth rate (CAGR) of 11.6%. This projected growth during the forecast period is driven by the adoption of artificial intelligence in diagnostics, the expansion of home-based and remote monitoring capabilities, the rise of precision medicine, the development of multi-biomarker panels, and an increasing demand for real-time cardiac monitoring. Key trends shaping this period include the adoption of point-of-care testing, the emergence of miniaturized and portable diagnostic devices, the advancement of biomarker multiplexing technologies, the practice of personalized cardiac risk profiling, and the integration of wearables for continuous cardiac monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
Cardiac Biomarkers Testing Market Growth Drivers: What Factors Are Accelerating Expansion?
The rising incidence of cardiovascular diseases is anticipated to propel the expansion of the cardiac biomarkers testing market in the future. Cardiovascular disease encompasses conditions that impact the heart or blood vessels. Cardiac biomarker tests are utilized to measure biomarker levels, enabling rapid assessment of heart attack severity and its extent. Consequently, a higher prevalence of cardiovascular diseases is expected to drive greater demand for cardiac biomarker testing solutions. For example, in January 2024, the American Heart Association, a non-profit organization based in the United States, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, reflecting a 4.0% increase from 224.4 per 100,000 in 2023. As a result, the growing prevalence of cardiovascular diseases is fueling the growth of the cardiac biomarkers testing market.
Cardiac Biomarkers Testing Market Segment Analysis And Revenue Opportunities
The cardiac biomarkers testing market covered in this report is segmented –
1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types
2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications
3) By End-User: Hospitals, Specialty Clinics
Cardiac Biomarkers Testing Market Trends: What Is Shaping Future Industry Growth?
Major players within the cardiac biomarker testing market are increasingly turning to strategic collaborations as a way to integrate technologies that detect early indicators of heart disease and enhance patient recovery. These partnerships encourage joint efforts among firms, driving the creation of cutting-edge diagnostic tools, broadening their market presence, and speeding up the deployment of next-generation testing solutions to support improved cardiovascular health outcomes. A notable example occurred in September 2024, when MediBuddy—an Indian healthcare technology firm offering a wide-ranging platform for telemedicine, health monitoring, and insurance support—joined forces with Philips, a Netherlands-based multinational conglomerate. Through this alliance, the goal is to strengthen cardiac care across India by embedding Philips’ HeartPrint technology, which facilitates ongoing tracking and assessment of cardiovascular risk. This progressive strategy equips users with sophisticated resources via the MediBuddy platform, encouraging the active and early management of heart health.
Cardiac Biomarkers Testing Market Leading Players Shaping Industry Direction
Major companies operating in the cardiac biomarkers testing market are Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation
Access The Complete Cardiac Biomarkers Testing Market Report:
Cardiac Biomarkers Testing Market Regional Analysis And Leading Geography
North America was the largest region in the cardiac biomarkers testing market in 2025. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
